Conditions: Hypertension
Keywords: Blood Pressure Hypertension Cortisol
Allocation: RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 63
Healthy volunteers: no

Brief summary:
This study determined the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in participants with hypertension.

Detailed description:

Arms:
arm 1: Participants received LCI699 0.5 mg, capsules, orally, once daily (QD), with or without food for up to 6 weeks. arm 2: Participants received LCI699 1.0 mg, capsules, orally, QD, with or without food for up to 6 weeks. arm 3: Participants received LCI699 1.0 mg, capsules, orally, twice daily (BID), with or without food for up to 6 weeks. arm 4: Participants received LCI699 2.0 mg, capsules, orally, QD, with or without food for up to 6 weeks. arm 5: Participants received LCI699-matching placebo, capsules, orally, QD or BID, with or without food for up to 6 weeks.

Interventions: intervention 1: LCI699-matching placebo intervention 2: LCI699
Intervention descriptions: intervention 1: LCI699-matching placebo oral capsules intervention 2: LCI699 oral capsules

Protocol document: